These findings suggest that the knockdown of USP35 could enhance the anti-tumor immunity of oncolytic virotherapy by increasing CD8+ T infiltration, decreasing M2 macrophage polarization, and promoting the expression of key inflammatory factors such as IFNβ, CXCL10, and CCL5. The gene discussed is CXCL10; the disease is neoplasm.